Abstract
Shionogi and GlaxoSmithKline, as the joint venture company Shionogi-GlaxoSmithKline Pharmaceuticals, is developing S-1360, an HIV integrase inhibitor as a potential treatment for HIV infection. As of October 2002, phase II trials were ongoing and launch is expected in 2004/2005.
MeSH terms
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / metabolism
-
Anti-HIV Agents / pharmacology*
-
Anti-HIV Agents / therapeutic use
-
Anti-HIV Agents / toxicity
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Furans
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV Integrase Inhibitors / adverse effects
-
HIV Integrase Inhibitors / metabolism
-
HIV Integrase Inhibitors / pharmacology*
-
HIV Integrase Inhibitors / therapeutic use
-
HIV Integrase Inhibitors / toxicity
-
Humans
-
Triazoles
Substances
-
Anti-HIV Agents
-
Furans
-
HIV Integrase Inhibitors
-
S 1360
-
Triazoles